Minority Health Archive

BiDil: Race Medicine Or Race Marketing?

Sankar, Pamela and Kahn, Jonathan (2005) BiDil: Race Medicine Or Race Marketing? Health Affairs, W5. pp. 455-463.

Full text not available from this repository.


Recent Food and Drug Administration (FDA) approval of the first drug with a race-specific indication has fueled the controversy over the meaning of race and ethnicity and raised questions over whether this move should be seen as an advance or a setback in the struggle to address disparities in health status associated with race. The drug, BiDil, combines two generics long recognized as benefiting patients with heart failure, irrespective of race or ethnicity. The push to bring these drugs to market as a race-specific treatment was motivated by the peculiarities of U.S. patent law and a willingness to exploit race to gain commercial and regulatory advantage.

Export/Citation:EndNote | BibTeX | Dublin Core | ASCII (Chicago style) | HTML Citation | OpenURL | Reference Manager
Social Networking:

Item Type: Article
Uncontrolled Keywords: BiDil, race, race medicine, Food and Drug Administration (FDA), heart failure, disparities, African American, black
Subjects: Health > Health Equity
Health > Health Equity > Bioethics
Health > Pharmacotherapy
Related URLs:
Depositing User: Kismet Loftin-Bell
Date Deposited: 12 Oct 2005
Last Modified: 03 Jun 2011 12:56
Link to this item (URI): http://health-equity.lib.umd.edu/id/eprint/275

Actions (login required)

View Item